Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

168.59
+1.901.14%
Volume:1.09M
Turnover:183.50M
Market Cap:405.90B
PE:29.12
High:169.90
Open:167.31
Low:167.05
Close:166.69
Loading ...

BUZZ-Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study

Reuters
·
Just now

Johnson & Johnson Gets Health Canada Approval for Lung Cancer Drug Combination

MT Newswires Live
·
42 mins ago

Johnson & Johnson: Health Canada authorizes Lazcluze/Rybrevant combo

TIPRANKS
·
54 mins ago

Johnson & Johnson's Investigational Colitis Treatment Meets Primary Endpoint in Phase 2b Trial

MT Newswires Live
·
1 hour ago

Health Canada Authorizes Lazcluze® (Lazertinib) in Combination With Rybrevant® (Amivantamab) as a First-Line Chemotherapy-Free Treatment for Patients With Egfr-Mutated Advanced Lung Cancer

THOMSON REUTERS
·
1 hour ago

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

CNW Group
·
1 hour ago

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

ACCESS Newswire
·
1 hour ago

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

THOMSON REUTERS
·
1 hour ago

J&J: Icotrokinra Was Well Tolerated

THOMSON REUTERS
·
1 hour ago

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

PR Newswire
·
1 hour ago

Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus

Zacks
·
3 hours ago

3 ETFs to Buy Now for Passive Dividend Income

Motley Fool
·
Yesterday

BRIEF-J&J Says Phase 3 Iconic-Advance 1&2 Studies Met Their Co-Primary Endpoints

Reuters
·
08 Mar

J&J - Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

THOMSON REUTERS
·
08 Mar

J&J - Phase 3 Iconic-Advance 1&2(E )Studies Met Their Co-Primary Endpoints

THOMSON REUTERS
·
08 Mar

Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis

PR Newswire
·
08 Mar